119 results about "High dosage" patented technology

A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng / mL)) / (dose (mg)) ratio of less than 5 and / or a (mean AUC(0-24),ss (h*ng / mL)) / (Absolute Neutrophil Count (cells / mm3)) ratio on day 22 of dosing of not greater than 1.25.

The invention relates to the field of nano medicines, in particular to a targeted medicine as well as a preparation method and application thereof. The invention provides a targeted drug. The targeted drug comprises a tissue-type plasminogen activator and a targeted peptide. Thrombus targeting modification is directly carried out on a thrombolytic drug rtPA which is most widely applied clinically by utilizing a chemical method, the defects of narrow treatment time window, high dosage and high bleeding risk of the rtPA are remarkably improved, the preparation process is simple and controllable, materials required for preparation are easy to obtain, the cost is low, and the application prospect is wide. The toxic effect and degradation problems of materials such as compounds are eliminated, other instruments and equipment are not needed in the treatment process, and clinical transformation application of thrombus targeted rtPA becomes possible.

The invention provides a composite collimator and a control method thereof, a radiotherapy system and a dose delivery method thereof, and relates to the technical field of radiotherapy, and the composite collimator comprises a grating and a diaphragm which are sequentially arranged in the direction of a beam center axis, the plurality of blades move to form a grating channel through which a radiation beam can pass; the diaphragm is provided with a collimation channel, and the diaphragm can move relative to a beam center axis; when the diaphragm moves to enable the collimation channel to be located at the central axis of the beam, the radiation beam forms a focusing radiation field in a target area through the grating channel and the collimation channel; and when the diaphragm moves to enable the collimation channel to deviate from the beam center axis, the radiation beam forms a conformal radiation field in the target area through the grating channel. Through switching between the conformal radiation field and the focusing radiation field, a flexible irradiation scheme is provided, so that the dose distribution effect can be improved, and the radiotherapy effect is improved.

The invention provides a camptothecin prodrug. The camptothecin prodrug provided by the invention has higher drug retention in the liposome and better stability, and the prodrug liposome can maintain long-time plasma concentration in plasma. In-vitro characterization of the camptothecin prodrug liposome shows that the camptothecin prodrug liposome has higher encapsulation efficiency, drug loading capacity and stability, and can achieve a slow release effect in plasma; the experimental result on the cellular level shows that the compound has higher cellular uptake rate; in-vivo experiments prove that the compound has a better tumor accumulation effect and antitumor activity, can tolerate a higher dosage, and has higher biological safety.

A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and / or abscopal effects.

A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.

To provide methods of treating a human subject having non-neurological manifestations of acid sphingomyelinase deficiency (ASMD), and in certain embodiments, NPD subtype B.SOLUTION: A method for treating a human subject having an acid sphingomyelinase deficiency comprises: (a) a regimen for debulking an accumulated sphingomyelin substrate in the human subject including (i) administering an initial low non-toxic dose of an acid sphingomyelinase (ASM) to the human subject, and (ii) administering successively higher doses of ASM to the human subject and monitoring the subject for one or more adverse side effects after each successive dose as indicated by elevated bilirubin or a related adverse event; and (b) a maintenance regimen comprising administering a dose equal to or less than the highest dose tolerated by the subject as a maintenance dose for the subject.SELECTED DRAWING: None

The invention relates to a nintedanib dry powder inhalant as well as a preparation method and application thereof. The dry powder inhalant comprises nintedanib and magnesium stearate. According to the nintedanib dry powder inhalant, by controlling the adding proportion of magnesium stearate and the particle size distribution of co-micro powder, the dosage of fine particles can be remarkably increased, the nintedanib dry powder inhalant still has the high dosage of fine particles under the high drug loading capacity, the drug bioavailability is high, and the safety risk of a patient in the medication period can be reduced. Meanwhile, the preparation method of the nintedanib dry powder inhalant is simple and controllable, and the final product is safe, reliable and high in stability.

Disclosed are high dose gastric retentive, extended-release lithium salt dosage forms suitable for once a day administration.

The invention provides a pharmaceutical composition for treating non-small cell lung cancer and application of the pharmaceutical composition. The pharmaceutical composition comprises gefitinib, erlotinib, afatinib, neratinib, osimertinib and the like which serve as active ingredients. The pharmaceutical composition disclosed by the invention can simultaneously contain various EGFR inhibitors as active ingredients, and the active ingredients are controlled at ultra-low dosage, so that the pharmaceutical composition not only can ensure the treatment effect, even the drug effect of the pharmaceutical composition is obviously superior to that of a high-dosage EGFR inhibitor independent administration group, but also can ensure the safety, and the pharmaceutical composition is suitable for clinical application. And after the active components are combined, a good synergistic effect is achieved, and more importantly, the occurrence of drug resistance can be remarkably reduced or even resisted. In a lung cancer cell culture experiment, the EGFR inhibitor independent administration group has a drug resistance phenomenon at the earliest 20 days, but the pharmaceutical composition group still has no drug resistance phenomenon after 160 days of administration.

A water remediation system and accompanying method includes remediation by reducing the concentration of nutrients in the water and dosing the water with metal ions. It has been found that through a combination of reducing nutrients present in the water and treating with metal ions, the requirement to treat with high chemical dosages is removed.

The invention discloses a screening and dosage determining method of a grape heat resistance inducer, and belongs to the technical field of plant stress resistance physiology and cultivation. The method comprises the following steps: soaking grape leaf wafers in inducers with different concentrations, and carrying out heat treatment under a plurality of temperature gradients; determining a chlorophyll OJIP rapid fluorescence parameter and constructing a heat resistance comprehensive index, and further calculating a normalized relative heat resistance improvement value; fitting a quantitative relation with the concentration by using a single-peak dose-effect model containing a high-dose inhibition item; statistical inference is carried out by adopting Bootstrap resampling, and a stable and effective recommended application concentration in a wide temperature range is finally determined by analyzing a common intersection or a statistical median of effective concentration intervals under multiple temperatures. The method realizes indoor rapid and quantitative screening, can realize quantitative comparison of induction intensity and dose sensitivity of different inducers under a unified evaluation system, and can be used for identifying heat resistance of grapes.

The invention discloses a hexapeptide LR6 with anti-inflammatory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and the hexapeptide LR6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide LR6 is identified from spirulina platensis proteolysis liquid and has potential interaction with Keap1, an LPS-induced RAW264.7 cell test shows that TNF-alpha, IL-1beta and IL-10 can be remarkably inhibited by treatment of low-dose (200mM) and high-dose (400mM) hexapeptide LR6, the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone, and the inhibition effect of the high-dose hexapeptide LR6 is superior to that of positive control dexamethasone. Compared with dexamethasone, the hexapeptide LR6 has a better anti-inflammatory effect and can be used for preparing anti-inflammatory drugs.

The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w / w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w / w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w / w tebipenem pivoxil HBr, 5-25% w / w of a diluent, 0.5 to 5% w / w of a glidant, 0.5 to 5% w / w of a lubricant, and optionally 0.5 to 5% w / w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept extended periods between doses.

Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

This invention discloses an ultrafine particle soil fluidized solidifier and an intelligent pile-forming process for in-situ pre-mixed fluidized solidified soil. The solidifier comprises cement, granulated blast furnace slag powder, and other main solidifying materials, along with an organic polymeric dispersant. Through the action of a low dosage of the organic polymeric dispersant, the plastic-to-fluid transition of the cohesive solidified soil is achieved, solving the technological challenges in preparing ultrafine particle fluidized solidified materials with high dosage, low moisture content, and high strength. An innovative airtight construction process is proposed. By introducing a pressurized airflow during mixing, the gas phase space of the ultrafine particle fluidized solidified material is increased, providing space for the growth of hydration product crystals and suppressing the strength-reducing effect of the organic polymeric dispersant on the solidified soil. This achieves rapid mixing of the solidifying material and the solidified soil, significantly improving the construction efficiency of in-situ soil solidification.

A dosing mechanism for a drug delivery device is provided for selecting and dispensing user-variable doses of a medicament. The mechanism includes a housing, a piston rod, and a drive configured to rotate the piston rod and / or a movement application component directly engaged with the piston rod in a dispense rotational direction relative to the housing. A rotational end-stop mechanism terminates dose dispense and includes a first engagement element rotationally fixed to the piston rod and / or the movement application component, and a second engagement element that is constrained against rotation relative to the housing at the end of dose dispense. To improve dose accuracy, the second engagement element remains out of direct engagement with the first engagement element during dispensing, and only at the end of dose dispense directly engages the first engagement element to provide a rotational stop. A drug delivery device incorporating the dosing mechanism is also disclosed.

Aerosolization devices and procedures are described that improve air-jet dry powder inhaler (DPI) technologies and other types of inhalers, thereby optimizing aerosolization performance and expanding dosing capacity. One example device includes a variable-sized aerosolization chamber and an adjustment mechanism that allows the chamber size to be changed between activations. During use, the distance between the aerosolization chamber's air channel and the top of the powder bed remains virtually constant, even as the powder bed empties with each successive activation of the device.

An exhaust aftertreatment system comprises a pump; reagent dosing devices arranged in series with each other; and a controller. The controller comprises a dosing device diagnostic circuit configured to in a first stage measuring a first stage diagnostic indicating an amount of reagent dosed by all the reagent dosing devices, and comparing the measured first stage diagnostic with a nominal first stage diagnostic. If a deviation exceeds nominal performance then in a second stage of evaluation is triggered to identify a faulty reagent dosing device, wherein all the further reagent dosing devices are set to dose at a low quantity while simultaneously activating the first reagent dosing device to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and measuring a second stage diagnostic. The measured second stage diagnostic is compared with a nominal second stage diagnostic for determining if the first dosing device is operating correctly or faulty. In a third stage the first reagent dosing device is set to dose at a low quantity while simultaneously only one of the further reagent dosing devices is activated to dose at two operating points, i.e. at a low dosing quantity and at medium or high dosing quantity and a third stage diagnostic is measured and compared with a nominal second stage diagnostic for determining if said only one of said further reagent dosing devices is operating correctly or faulty.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and / or abscopal effects.

The utility model discloses an antibacterial softener storage and use device with an accurate proportioning structure, and aims to provide the antibacterial softener storage and use device with the accurate proportioning structure, which has the advantages that the taking convenience is improved, and the dosage precision is high. The device comprises a base; the bracket is connected with the base; the storage box is connected with the support, and the storage box is connected with a switch assembly; the material receiving assembly is connected with the base, the material receiving assembly is provided with a quantifying cup, and a quantifying plate is movably connected with the base; and the ratio control assembly is connected with the support, the ratio control assembly is provided with a material return pipe, and the material return pipe is connected with the storage box and the quantitative cup. The device has the beneficial effects that various raw materials of the antibacterial softening and moistening agent can be quickly discharged in the device through the storage device, and meanwhile, the quantity can be accurately controlled; accurate control of the proportion is realized; the structural connection and operation stability is improved, and feeding and discharging are convenient to store; the operation efficiency is improved.

The present invention relates to a regimen for the treatment of angiogenic eye diseases, such as nAMD, characterized by a high dose of aflibercept and an extended dose interval.

The present invention describes the combination of a 5HT3-antagonist and / or NK1-antagonist with pramipexole to reduce or eliminate the adverse effects associated with the use of pramipexole and to enable the use of high doses of pramipexole for treating anhedonia.

A dry powder inhaler for pulmonary or nasal use, comprising at least an inhaler body (201) and a cartridge (203) with a plurality of powder compartments (205) each including one dose of a drug. The body (201) has an opening (204) shaped for receiving the cartridge (203) and the plastic body recess (215) and the detent (218) to allow a controlled advancement and turning movement of the cartridge (203) relative to the body (201) for sequentially delivering each of the plurality of unit doses filled into the cartridge compartments (205). The inhaler construction is suitable for filling the plurality of unit doses into the compartments (205) with the cartridge (203) assembled into the body (201). The invention affords a large dose inhaler of single-use and low cost that improves industrial filling and manufacturing cost for the delivery of high dosages of inhaled medicines.

The invention relates to a traditional Chinese medicine preparation, in particular to application of a compound live brain soothing capsule in preparation of a medicament for treating insomnia. The dosage of the medicine is 200 mg / kg. Experiments show that the sleep improvement effect of the compound Shuonaoshu capsule on an anesthesia reviving experiment evaluation test medicine, a high-dose group (200 mg / kg) of the compound Shuonaoshu capsule can effectively prolong sleep time, dose dependence exists, sleep quality can be moderately improved, the higher the concentration is, the more obvious the improvement effect is, and the more obvious the effect is. The invention reveals that the compound Liangjinshu capsule has a treatment effect on insomnia, and is expected to provide a certain experimental basis for the development of new drugs for insomnia.

The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept extended periods between doses.

Provided are formulations and methods to treat ultra-potent synthetic opioid overdose with high dose Naloxone formulations comprising naloxone hydrochloride or a pharmaceutically acceptable salt thereof, one or more preservatives, one or more buffering agents, a tonicity modifier, and optionally a pH modifier.